ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunot...
ImmunityBio, Inc. (IBRX)
Company Research
Source: Business Wire
Phase 2 data presented at the World Conference on Lung Cancer showing a prolonged median overall survival of over 14 months in 2nd and 3rd line NSCLC cancer patients who progressed on checkpoint inhibitors such as KEYTRUDA (pembrolizumab) and OPDIVO (nivolumab)ANKTIVA plus KEYTRUDA or OPDIVO rescued T cell activity in these patients who progressed on the same checkpoint inhibitor with overall survival of 57% at 12 months Long-term survival was independent of PDL1 tumor status and independent of 2nd or 3rd line of therapy The data continues to validate the mechanism of action of ANKTIVA in activating NK, CD8 killer, and Memory T cells resulting in prolonged overall survival in patients with advanced cancers Data supports global launch of Phase 3 randomized control of ResQ trials of ANKTIVA plus KEYTRUDA or OPDIVO in 1st and 2nd line NSCLC (ResQ301 and ResQ302) versus standard of care CULVER CITY, Calif.--(BUSINESS WIRE)--Immunotherapy innovator ImmunityBio, Inc. (NASDAQ: IBRX), toda
Show less
Read more
Impact Snapshot
Event Time:
IBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IBRX alerts
High impacting ImmunityBio, Inc. news events
Weekly update
A roundup of the hottest topics
IBRX
News
- Immunitybio Inc. (IBRX): Fast-Growing Penny Stock To Consider [Yahoo! Finance]Yahoo! Finance
- A Billionaire Saved A Nonprofit. Then Things Got Ugly [Forbes]Forbes
- ImmunityBio, Inc. (NASDAQ: IBRX) had its price target lowered by analysts at Piper Sandler from $6.00 to $4.75. They now have a "neutral" rating on the stock.MarketBeat
- ImmunityBio's Anktiva: Promising, But Organizational Complexity Keeps Me Cautious [Seeking Alpha]Seeking Alpha
- ImmunityBio: Anktiva's Launch Progresses - Bladder Cancer Drug May Be 'Real Deal' [Seeking Alpha]Seeking Alpha
IBRX
Earnings
- 5/9/24 - Miss
IBRX
Sec Filings
- 8/12/24 - Form 10-Q
- 7/18/24 - Form 8-K
- IBRX's page on the SEC website